ABILITY Neurotech

ABILITY Neurotech is a biotechnology company focused on developing novel small molecule therapies for neurodegenerative diseases, specifically targeting GBA1-linked Parkinson's disease. The company's lead candidate, AB-1001, is a brain-penetrant glucocerebrosidase (GCase) activator designed to restore lysosomal function and reduce the accumulation of toxic proteins. By addressing the genetic drivers of Parkinson's, ABILITY aims to provide disease-modifying treatments for patients with high unmet medical needs. The firm is supported by leading venture capital firms and a management team with extensive experience in CNS drug discovery. ABILITY's approach leverages precision medicine to target specific patient populations defined by genetic biomarkers.